Skip to main content

Table 3 Management, Complication and Follow-up

From: Management guidelines of penile cancer- a contemporary review of sub-Saharan Africa

StudyLocality of lesionSurgeryChemo/RadiotherapyComplicationFollow-up
Ngendaho et al. [7]Glans: 46.7%Partial Penectomy: 80%
Total Penectomy:13.3%
Penectomy + ILND:33.3%
N/ASSI:10%; Lymphocele:10%, Skin necrosis, Death, Meatal stenosis0% recurrence at 6 months
Diallo et al. [8]Glans: 33.3%
Glans + Penile Shaft: 66.7%
PP: 16.7%
TP + ILND: 16.7%
Emasculation:16.7%
Decline Treatment:33.3%
N/AN/A50% Loss to follow-up
1-year mortality 33.3%
Magoha et al. [9]Glans: 43.6%
Glans + Penile Shaft: 21.8%
Prepuce: 12.7%
Circumcision: 3.6%
Local Excision + Rad: 7.2%
PP + Rad: 20.1%
PP + Chemo: 5.5%
PP + Chemo + rad: 10.9%
TP + Rad: 14.5%
Rad alone: 9.1%
Chemo + Rad: 10.9%
N/AN/A
Gueye et al. [11]Glans: 36.4%
Glans + Shaft: 45.5%
Partial Penectomy: 18.2%
Total Penectomy: 9.1%
Decline Treatment: 72.7%
N/AN/A100% Loss to Follow-up
Ajekigbe et al [12]Penile Shaft: 42.9%N/AN/AN/AN/A
Sow et al. [13]Glans: 62.5%%
Shaft: 12.5%
Prepuce: 25%
TP: 37.5%
Emasculation + ILND:12.5%
N/AN/ALoss to follow-up: 50%
Abdulkadir et al. [14]Glans: 50%
Glans + Prepuce:33.3%
Shaft: 16.7%
    
Chayla et al. [15]Glans: 60.1%
Glans + Shaft: 13.6%
Prepuce: 7.6%
Partial penectomy: 63.1%
Total Penectomy:10.8%
ILND: 16.8%
Penile sparing: 9.3%
Chemo: 5.9%
Rad: 5.1%
SSI: 44.8%;
DVT: 15.5%
Chronic Pain: 13.8%
Scrotal edema: 10.3%
76.1% loss to follow-up at 5 years
Mortality:10%
Recurrence: 5.3%
Sow et al. [16]Glans: 12.5%
Glans + Shaft: 62.5%
Shaft: 25%
Partial Penectomy: 62.5%
TP + ILND: 12.5%
Decline Treatment: 25%
  25% loss to follow-up
Recurrence: 12.5%
Death: 12.5%
  1. DVT: Chemo: Chemotherapy; Deep Venous Thrombosis, ILND: Inguinal Lymph Node Dissection; N/A: Not Available; PP: Partial Penectomy; Rad: Radiotherapy; SSI: Surgical Site Infection; TP: Total Penectomy